LUNG
Pulmonx Corp.
NASDAQ · Healthcare · Medical - Devices · US
$2.07
+4.55%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.99
From 52W high−20.38%
Volume429837.00
Market cap$88.90M
P/E (TTM)—
P/S (TTM)1.0x
Div yield—
Key dataSep 18, 2026
Open
$1.99
From 52W high
−20.38%
Volume
429837.00
Market cap
$88.90M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.1x
P/E (TTM)
—
RSI (14)
47.8
MomentumView details →
1D Return
+4.55%
YTD Return
−8.82%
SummaryUpdated Jun 1, 2026
Pulmonx Corporation (NASDAQ:LUNG) is a medical technology company founded in 1995 and headquartered in Redwood City, California. The company specializes in developing and commercializing minimally invasive devices for treating chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Since going public in October 2020, Pulmonx has focused on expanding its flagship Zephyr Endobronchial Valve system globally while developing complementary technologies to address the broader COPD patient population.
Similar companies
Latest newsMore news →